文献速递心律失常冠心病心力衰竭与心肌病

雷诺嗪在高危植入型心律转复除颤器患者中的应用:RAID试验

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

RAID试验为双盲安慰剂对照研究,纳入1012例缺血性或非缺血性心肌病高危ICD患者,随机接受雷诺嗪1000mg每日两次或安慰剂。主要终点(需适当ICD治疗的VT/VF或死亡)风险比为0.84(95%CI 0.67-1.05;P=0.117),未达统计学显著;预设次要分析中雷诺嗪与复发性VT/VF需ICD治疗风险降低相关(HR 0.70;95%CI 0.51-0.96;P=0.028)。

要点

  • 雷诺嗪未显著降低高危ICD患者首次VT/VF或死亡风险(HR 0.84,P=0.117)。
  • 预设次要分析显示雷诺嗪与复发性VT/VF需ICD治疗风险降低相关(HR 0.70,P=0.028)。
  • 研究主要终点把握度不足,其他预设次要终点无显著治疗效应。

核心结论

  • 在高危ICD患者中,雷诺嗪治疗未显著降低首次VT/VF或死亡的发生率,但研究对主要终点的检验把握度不足。
  • 预设次要分析中,雷诺嗪与复发性VT/VF需ICD治疗风险显著降低相关,且无死亡率增加的证据。

研究设计与样本

  • 双盲、安慰剂对照临床试验,纳入高危ICD患者,随机分配至雷诺嗪1000mg每日两次或安慰剂。
  • 共1012例ICD患者(雷诺嗪组510例,安慰剂组502例),平均年龄64±10岁,女性占18%。
  • 随访28±16个月,主要终点为需适当ICD治疗的VT或VF或死亡(以先发生者为准)。

主要发现

  • 随访期间372例(37%)发生主要终点,270例(27%)发生VT或VF,148例(15%)死亡。
  • 雷诺嗪组253例(49.6%)与安慰剂组199例(39.6%)停用盲法研究药物(P=0.001)。
  • 雷诺嗪对比安慰剂的主要终点风险比为0.84(95%CI 0.67-1.05;P=0.117)。
  • 预设次要分析中,雷诺嗪组复发性VT/VF需ICD治疗的风险比为0.70(95%CI 0.51-0.96;P=0.028)。
  • 其他预设次要分析(包括主要终点各组分、不适当放电、心脏住院和生活质量)无显著治疗效应。

关键数值与推荐

  • 主要终点风险比0.84(95%CI 0.67-1.05;P=0.117),未达统计学显著。
  • 复发性VT/VF需ICD治疗的风险比0.70(95%CI 0.51-0.96;P=0.028),为边际显著。

临床怎么用

  • 对于高危ICD患者,雷诺嗪未显示可显著减少首次VT/VF或死亡,不应基于本研究将其用于该终点的常规预防。
  • 预设次要分析提示雷诺嗪可能减少复发性VT/VF需ICD治疗,但需结合停药率较高及研究把握度不足谨慎解读。

局限性

  • 研究对主要终点的检验把握度不足,可能无法检出有临床意义的差异。
  • 盲法研究药物停药率较高(雷诺嗪组49.6%,安慰剂组39.6%),可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs). OBJECTIVES: This study aimed to determine whether ranolazine administration decreases the likelihood of VT, VF, or death in patients with an ICD. METHODS: This was double-blind, placebo-controlled clinical trial in which high-risk ICD patients with ischemic or nonischemic cardiomyopathy were randomized to 1,000 mg ranolazine twice a day or placebo. The primary endpoint was VT or VF requiring appropriate ICD therapy or death, whichever occurred first. Pre-specified secondary endpoints included ICD shock for VT, VF, or death and recurrent VT or VF requiring ICD therapy. RESULTS: Among 1,012 ICD patients (510 randomized to ranolazine and 502 to placebo) the mean age was 64 ± 10 years and 18% were women. During 28 ± 16 months of follow-up there were 372 (37%) patients with primary endpoint, 270 (27%) patients with VT or VF, and 148 (15%) deaths. The blinded study drug was discontinued in 199 (39.6%) patients receiving placebo and in 253 (49.6%) patients receiving ranolazine (p = 0.001). The hazard ratio for ranolazine versus placebo was 0.84 (95% confidence interval: 0.67 to 1.05; p = 0.117) for VT, VF, or death. In a pre-specified secondary analysis, patients randomized to ranolazine had a marginally significant lower risk of ICD therapies for recurrent VT or VF (hazard ratio: 0.70; 95% confidence interval: 0.51 to 0.96; p = 0.028). There were no other significant treatment effects in other pre-specified secondary analyses, which included individual components of the primary endpoint, inappropriate shocks, cardiac hospitalizations, and quality of life. CONCLUSIONS: In high-risk ICD patients, treatment with ranolazine did not significantly reduce the incidence of the first VT or VF, or death. However, the study was underpowered to detect a difference in the primary endpoint. In prespecified secondary endpoint analyses, ranolazine administration was associated with a significant reduction in recurrent VT or VF requiring ICD therapy without evidence for increased mortality. (Ranolazine Implantable Cardioverter-Defibrillator Trial [RAID]; NCT01215253).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zareba W, Daubert JP, Beck CA, et al. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. J Am Coll Cardiol. 2018. PMID: 30071993. doi:10.1016/j.jacc.2018.04.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。